NFA
ATRA icon

Nationwide Fund Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Nationwide Fund Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-539
Closed -$223K – 180
2017
Q3 		$223K Hold
539
– – ﹤0.01% 2586
2017
Q2 		$189K Hold
539
– – ﹤0.01% 2643
2017
Q1 		$277K Sell
539
-32
-6% -$13.2K ﹤0.01% 2449
2016
Q4 		$203K Sell
571
-33
-5% -$14K ﹤0.01% 2589
2016
Q3 		$323K Hold
604
– – ﹤0.01% 2397
2016
Q2 		$340K Buy
604
+166
+38% +$79.7K ﹤0.01% 2355
2016
Q1 		$208K Hold
438
– – ﹤0.01% 2520
2015
Q4 		$289K Buy
438
+8
+2% +$6.05K ﹤0.01% 2372
2015
Q3 		$338K Buy
430
+55
+15% +$67.1K ﹤0.01% 2316
2015
Q2 		$494K Buy
375
+194
+107% +$223K ﹤0.01% 2254
2015
Q1 		$188K Buy
181
+13
+8% +$8.59K ﹤0.01% 2723
2014
Q4 		$112K Buy
+168
New +$103K ﹤0.01% 2877

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Nationwide Fund Advisors's ATRA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2017, closing a stake of 539 shares — an estimated $223K sold.

Nationwide Fund Advisors first reported a position in ATRA in Q4 2014 and held it in 12 quarters. The position peaked at $494K in Q2 2015. 86 funds tracked by Wall St. Rank hold ATRA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Atara Biotherapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 539 Atara Biotherapeutics shares in Q4 2017, an estimated $223K.
  • Nationwide Fund Advisors first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 12 quarters.
  • Nationwide Fund Advisors's Atara Biotherapeutics position peaked at $494K in Q2 2015.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.